The functions and efficacy of sotolaxib (AMG510)

Sotoracib (AMG510)is indicated for the treatment of adult patients with KRAS G12C- mutated locally advanced or metastatic non-small cell lung cancer(NSCLC). Sotorracib is a drug called a KRAS inhibitor, which works by blocking the activity of abnormal proteins that signal cancer cells to multiply, which can help stop or slow the spread of cancer cells.

Sotorracib (AMG510) is optimistic in the treatment of lung cancer. After reviewing a large amount of literature and analyzing multiple clinical trial reports, we found that the half-life of sotoraxib is 5.5 hours, and the disease control rate (DCR) was 80.6%, the objective response rate (ORR) was 37.1%, and the duration of response (DOR) was 6.8 months, the median progression-free survival (mPFS) was 13.6 months, and the median overall survival (mOS) was 12.5 months, the adverse reaction rate was 69.8%, and the incidence rate of grade 3 or above adverse reactions was 19.8%.

Sotorasiib may cause side effects, including diarrhea, vomiting, nausea, constipation, loss of appetite, stomach pain, fatigue, muscle or bone pain, and joint pain. Keep this medication in a tightly sealed container out of the reach of children. Store at room temperature, away from light, excessive heat and moisture(Do not place in bathroom). Keep all medicines out of the sight and reach of children. Many containers (such as weekly pills and eye drops, creams, patches and inhalers) are not child-safe and young children can open them easily. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.